STOCKHOLM, April 26, 2018 /PRNewswire/ -- "Data provide strong support for our claims that ATOR-1015 is a next generation bispecific CTLA-4 antibody with tumor-directed properties." See CEO Per Norlén's comments. Significant events January-March 2018• Alligator Bioscience...
from PR Newswire: //https://ift.tt/2HsOWtR
No comments:
Post a Comment